The approval covers both monotherapy and combination therapy options, including use of chemotherapy and combination therapy options including use with chemotherapy or cabozantinib, according to a Dec. 27 news release from the agency.
The approval is based on results from a randomized, open-label trial in 495 patients with advanced or metastatic clear cell renal cell carcinoma who received either subcutaneous nivolumab and hyaluronidase-nvhy or intravenous nivolumab.
The subcutaneous version showed a 24% overall response rate compared to 18% for the intravenous form.
The new injectable form offers more flexible dosing options, administered every 2 to 4 weeks depending on the treatment regimen.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.